ABSTRACT
Atopic dermatitis (AD) is one of the most common inflammatory skin diseases. But the great heterogeneity of AD makes it difficult to design an accurate diagnostic pipeline based on traditional diagnostic methods. In other words, the AD diagnosis has suffered from an inaccurate bottleneck. Thus, it is necessary to develop a novel and accurate diagnostic model to supplement existing methods. The recent development of advanced gene sequencing technologies enables potential in accurate AD diagnosis. Inspired by this, we developed an accurate AD diagnosis based on transcriptomic data in skin tissue. Using these data of 149 subjects, including AD patients and healthy controls, from Gene Expression Omnibus (GEO) database, we screened differentially expressed genes (DEGs) of AD and identified six critical genes (PPP4R1, SERPINB4, S100A7, S100A9, BTC, and GALNT6) by random forest classifier. In a follow-up study of these genes, we constructed a neural network model (average AUC=0.943) to automatically distinguish subjects with AD from healthy controls. Among these critical genes, we found that PPP4R1 and GALNT6 had never been reported to be associated with AD. Although further replications in other cohorts are needed, our findings suggest that these genes may be developed into useful biomarkers of AD diagnosis and may provide invaluable clues or perspectives for further researches on the pathogenesis of AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by National Natural Science Foundation of China (No.31972856), Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases (No. 2018B030322012) and Top Talents Project of Guangdong Provincial Hospital of Traditional Chinese Medicine(No.BJ2022YL08).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at: https://www.ncbi.nlm.nih.gov/geo/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced are available online at https://www.ncbi.nlm.nih.gov/geo/
